INTRODUCTION:Varenicline, a first-line non-nicotine medication, has not been evaluated in Black smokers, and limited attention has been paid to pharmacotherapy adherence in smoking cessation trials. This pilot study estimated quit rates for Black smokers treated withvarenicline and tested a behavioral intervention to aid varenicline adherence. METHODS:Seventy-two Black smokers (>10 cigarettes per day; cpd) were randomly assigned to adherence support (AS; n = 36) or standard care (n = 36). All participants received 3 months of varenicline and a single counseling session focused on making a quit plan. AS participants received 5 additional counseling sessions to encourage medication use. Outcome measures included salivary cotinine, and carbon monoxide confirmed smoking abstinence, reductions in self-reported cpd, and pill counts of varenicline adherence at Months 1, 2, and 3. RESULTS: Sixty-one participants (84.7%) completed follow-up at Month 3. Participants were female (62.5%), 46.8 years of age, and smoked 16.3 cpd. No treatment group differences were found on the smoking or adherence outcome measures (p > .05). Collapsing across treatment, varenicline adherence was adequate (86.1%), yet despite a reduction of 12.2 (6.5) cpd from baseline to Month 3 (p < 0.001), only 23.6% were confirmed quit at Month 3. Participants who were quit at Month 3 had higher varenicline adherence rates (95.8%) than those who continued to smoke (80.8%, p ≤ .05). CONCLUSIONS: Studies are needed to examine the efficacy of varenicline among Black smokers. Interventions to facilitate adherence to pharmacotherapy warrant further attention as adherence is linked to improved tobacco abstinence.
RCT Entities:
INTRODUCTION:Varenicline, a first-line non-nicotine medication, has not been evaluated in Black smokers, and limited attention has been paid to pharmacotherapy adherence in smoking cessation trials. This pilot study estimated quit rates for Black smokers treated with varenicline and tested a behavioral intervention to aid varenicline adherence. METHODS: Seventy-two Black smokers (>10 cigarettes per day; cpd) were randomly assigned to adherence support (AS; n = 36) or standard care (n = 36). All participants received 3 months of varenicline and a single counseling session focused on making a quit plan. AS participants received 5 additional counseling sessions to encourage medication use. Outcome measures included salivary cotinine, and carbon monoxide confirmed smoking abstinence, reductions in self-reported cpd, and pill counts of varenicline adherence at Months 1, 2, and 3. RESULTS: Sixty-one participants (84.7%) completed follow-up at Month 3. Participants were female (62.5%), 46.8 years of age, and smoked 16.3 cpd. No treatment group differences were found on the smoking or adherence outcome measures (p > .05). Collapsing across treatment, varenicline adherence was adequate (86.1%), yet despite a reduction of 12.2 (6.5) cpd from baseline to Month 3 (p < 0.001), only 23.6% were confirmed quit at Month 3. Participants who were quit at Month 3 had higher varenicline adherence rates (95.8%) than those who continued to smoke (80.8%, p ≤ .05). CONCLUSIONS: Studies are needed to examine the efficacy of varenicline among Black smokers. Interventions to facilitate adherence to pharmacotherapy warrant further attention as adherence is linked to improved tobacco abstinence.
Authors: Nicole Nollen; Jasjit S Ahluwalia; Matthew S Mayo; Kim Richter; Won S Choi; Kolawole S Okuyemi; Ken Resnicow Journal: Health Educ Behav Date: 2007-06-18
Authors: Karen L Cropsey; Michael F Weaver; Gloria D Eldridge; Gabriela C Villalobos; Al M Best; Maxine L Stitzer Journal: Nicotine Tob Res Date: 2009-04-22 Impact factor: 4.244
Authors: Maya L Petersen; Yue Wang; Mark J van der Laan; David Guzman; Elise Riley; David R Bangsberg Journal: Clin Infect Dis Date: 2007-08-20 Impact factor: 9.079
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Taneisha S Buchanan; Carla J Berg; Lisa Sanderson Cox; Niaman Nazir; Neal L Benowitz; Lisa Yu; Olivia Yturralde; Peyton Jacob; Won S Choi; Jasjit S Ahluwalia; Nicole L Nollen Journal: Nicotine Tob Res Date: 2012-02-24 Impact factor: 4.244
Authors: Kelly E Dunn; Taylor F Marcus; Cynthia Kim; Jennifer R Schroeder; Ryan Vandrey; Annie Umbricht Journal: Nicotine Tob Res Date: 2015-10-17 Impact factor: 4.244
Authors: Donna Shelley; Tuo-Yen Tseng; Mirelis Gonzalez; Paul Krebs; Selena Wong; Robert Furberg; Scott Sherman; Antoinette Schoenthaler; Anthony Urbina; Charles M Cleland Journal: Nicotine Tob Res Date: 2015-08 Impact factor: 4.244
Authors: Tuo-Yen Tseng; Paul Krebs; Antoinette Schoenthaler; Selena Wong; Scott Sherman; Mirelis Gonzalez; Antonio Urbina; Charles M Cleland; Donna Shelley Journal: AIDS Behav Date: 2017-07
Authors: Nicole L Nollen; Matthew S Mayo; Jasjit S Ahluwalia; Rachel F Tyndale; Neal L Benowitz; Babalola Faseru; Taneisha S Buchanan; Lisa Sanderson Cox Journal: Ann Behav Med Date: 2013-12
Authors: Sherry A McKee; Philip H Smith; Mira Kaufman; Carolyn M Mazure; Andrea H Weinberger Journal: Nicotine Tob Res Date: 2015-10-06 Impact factor: 4.244
Authors: Nicole L Nollen; Lisa Sanderson Cox; Qing Yu; Edward F Ellerbeck; Taneisha S Scheuermann; Neal L Benowitz; Rachel F Tyndale; Matthew S Mayo; Jasjit S Ahluwalia Journal: Contemp Clin Trials Date: 2015-12-05 Impact factor: 2.226
Authors: Raka Jain; Sonali Jhanjee; Veena Jain; Tina Gupta; Swati Mittal; Patricia Goelz; E Paul Wileyto; Robert A Schnoll Journal: Nicotine Tob Res Date: 2013-08-14 Impact factor: 4.244